After a rough start to the year, small- and mid-cap software stocks may be finding their footing. Goldman Sachs analyst Adam ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Minerals chair Roger Jackson says he is confident the explorer is on the cusp of significant cash generation, as it moves toward production at its Hill End gold project in NSW. “This capital ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...

By Christy Santhosh (Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta ...

Or sign-in if you have an account. The human mind really can go blank during consciousness, according to a new review that challenges the assumption people experience a constant flow of thoughts ...

Pittsburgh will have its own version of Manhattan’s High Line in coming years ... into a project informed by the community. This is a blank canvas for us.” The public will get the chance ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed for now on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a significant beat.

were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in line with Street expectations. For Q4, Vertex ...

BOSTON - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported fourth-quarter revenue that exceeded analyst estimates, driving its stock up 0.8% in after-hours trading Monday. The ...